Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.
  • July 19, 2022
  • Latest, People
Mondana Cook, Chief Operating Officer at PBD Biotech
Mondana Cook, Chief Operating Officer at PBD Biotech

Each day 4,100 people die from tuberculosis, a preventable disease. The ‘Global Plan to End TB’ is a costed public health plan that aims to cut deaths by 90% in eight years. A key recommendation of the report is to universally replace sputum microscopy with a rapid molecular diagnostic, such as Actiphage®, developed by PBD Biotech. Mondana Cook has joined the company as the Chief Operating Officer to progress its Actiphage diagnosis to meet this global challenge.

Mondana explains: “TB is a devastating disease which has personally touched my family. I feel passionately about making a contribution to the early diagnosis, treatment and eradication of this disease, which impacts the lives of millions of people worldwide.”

Mondana previously held positions as Chief Operating Officer at the precision medicine and diagnostics company Kinomica, was Director of Program Management at QIAGEN and has been involved in the development of a tuberculosis vaccine.

She says she was attracted to PBD Biotech by its mission: “To support the eradication of tuberculosis and related mycobacterial diseases through early-stage detection of carriers.”

PBD Biotech’s Actiphage diagnostic can identify the presence of live mycobacteria in blood at an early stage of infection, providing for the first time a way to screen vulnerable populations for TB and related diseases, before they become infectious or show clinical signs of the disease.

Mondana’s role is to further develop the Actiphage diagnostic. “I see my role as continuing the transition into products and global healthcare solutions. This will involve collaborations to further enhance the product development and clinical data packages, scale up of product manufacture, and achieve successful regulatory submissions and registrations. This work will culminate in the full product launch of a human diagnostic for TB.”

PBD Biotech has pursued the development of phage-based diagnostics for both human and animal health. It has recently launched a service for testing cattle and milk for Johne’s Disease caused by paratuberculosis (MAP) and has gained CPI funding to develop its quality management system, which is essential for human diagnostics.

Mondana explains the significance of this: “The CPI funding enables PBD Biotech to fast-track the implementation of a quality management system to ISO 13485. This is the standard used to ensure the quality and safety of medical devices and will underpin the use of the diagnostics to support food security and animal health, as well as support the development program for a human TB diagnostic.”

PBD Biotech CEO Jane Theaker has worked previously with Mondana: “I am delighted to welcome Mondana on board, bringing her international experience and knowledge of human diagnostics from major players in the industry. She joins at an exciting time for the company as early results from human trials are very promising. We are grateful to Geoff Gower in his role as interim Operations Director. His input has been invaluable in setting up a commercial Johne’s Disease testing service, which is growing rapidly in the UK and attracting interest from overseas.”

Tuberculosis is second only to Covid as a fatal infectious disease and a ‘Global Plan to End TB’ highlighted the critical need for new diagnostics for TB.

Mondana continues: “The identification of Mycobacteria responsible for disease is fundamental to accurate diagnosis and management of the disease. However, prompt identification of infection is difficult, as the current gold-standard diagnosis is based on culture of bacteria, which takes over 20 days to produce a result. This diagnostic for TB also relies on testing sputum, however 40% of adults with TB and the majority of children struggle to generate sputum.

“Actiphage identifies the presence of live mycobacteria in a blood sample and can be used to detect very low levels of infection, often before the symptoms have developed and the disease becomes contagious. It can also have a predictive role in identifying subjects with the infection at risk of developing the disease. 

“Estimates in the recent report suggest that with good diagnostics and a vaccine it would be possible to prevent 26.5million cases over eight years. I want to play my part in that success story – that is why I joined PBD Biotech.”

Share:

Related posts

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
TB Progression in humans

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022
Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive step towards achieving the United Nations political declaration to eliminate TB by 2030.
TB Progression in humans

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022
Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive...
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...
1 2 … 24 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More